Glucagon-like peptide-1 receptor agonists during pregnancy and lactation

2024/12/15 by Jonathan S. Zipursky, Tali Bogler, Cynthia Maxwell
Medicine · #Bariatric Surgery and Outcomes #Diabetes Treatment and Management #Gestational Diabetes Research and Management

paper · pdf · doi:10.1503/cmaj.240768

openalex publication_date 2024/12/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/30

Abstract

Semaglutide, liraglutide, lixisenatide, dulaglutide, and tirzepatide are the current GLP1RAs available in Canada. These are approved for the treatment of type 2 diabetes and obesity and have been used as off-label treatment for PCOS. Systematic reviews suggest that GLP1RAs can improve the

Related

• GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
• GLP-1 and the cardiovascular system
• GLP-1 receptor agonist treatment in women with polycystic ovary syndrome—a systematic review and meta-analysis
• Therapies based on GLP-1 receptor agonists: significance, challenges, and opportunities
• Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study